|We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. For example, here is how to disable FireFox ad content blocking while on Silicon Investor.|
Please also see discussions about PCYC under QLT area.
Pharmacyclics is a company with three products in clinical development
and multiple compounds in preclinical development. Their products are:
Gd-Tex (gadolinium texophyrin), a radiation sensitizer. This product
is in Phase I trials, which are still open for enrollment. They are
studying effects on brain metastases, as well as looking at MDT's
(maximum tolerable dose).
Lu-Tex (lutetium texaphyrin PCI-0123), a light activated drug being
studied for treatment of various cutaneous tumors, including Kaposis
Sarcoma, melanoma, breast CA, and others. It is in Phase I trials,
the interim results of which looked very favorable for both efficacy
and toxicity. In fact, it could be a very important compound when and
if they demonstrate its efficacy in trials, because the drug has a fairly
short half-life, which limits its toxicity.
Gadolite oral suspension, an MRI contrast agent for the GI tract. This
is in Phase III trials and a NDA has been filed.
I believe they will compete in a difficult but very promising market.
The real question will be what , if any, advantages will Lu-Tex
have over products being studied by QLT and PDT. The CEO of PCYC is
Rich Miller who founded IDEC pharmaceuticals and he is supposedly
a very bright guy and whatever he touches seems to work (both
scientifically and for the shareholders).
I am not a stock promoter nor am I a principal of the company,
but I have been watching PCYC for several months and just
bought some shares due to the recent weakness in its stock price, and
because of the potential for its products.
I would love to keep and ongoing discussion about this company.
|© 2019 Knight Sac Media. Data provided by IEX, Alpha Vantage, Coinbase, Binance, Fintel and CityFALCON News|